Pathology: mML - L1 - all population; mML - L1 - BRAF mutant; mML - L1 - BRAF wild;
| mML - L1 - all population | mML - L1 - BRAF mutant | mML - L1 - BRAF wild | ||||
| CheckMate 067 (N vs I ; all population), 2015 | CheckMate 064, 2016 | IMspire-150 (BRAF mutant), 2020 | IMspire-170, 2020 | CheckMate 066, 2015 | ||
| nivolumab alone | 2 | T1 | T1 | |||
| atezolizumab plus SoC | 1 | T1 | ||||
| atezolizumab plus cometinib | 1 | T1 | ||||
| nivolumab followed by ipilimumab | 1 | T1 | ||||
| placebo plus SoC | 0 | T0 | ||||
| pembrolizumab alone | 0 | T0 | ||||
| ipilimumab followed by nivolumab | 0 | T0 | ||||
| ipilimumab alone | 0 | T0 | ||||
| dacarbazine | 0 | T0 | ||||